Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how he felt the multidisciplinary nature of the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®) was useful for future practice. Humphrey also talked about utilizing tumor boards where clinicians from different departments can discuss current topics.

Transcript:

One of the reasons I so enjoy this conference is the multidisciplinary nature. There’s directional learning and I’ve learned so much from my clinical colleagues today about their management based upon our diagnosis, for example. I think the same is true for when we present our diagnostic approach and how that diagnosis would influence them and their patient management. That multidisciplinary nature [for] taking care of patients with cancer, any cancer, is so vital.

I also appreciate that locally at Yale where we have weekly tumor boards, we have interactions amongst all of us including medical oncologists, urologist, interventional radiologists, diagnostic radiologists, and pathologists. Only by all of all of us having an input can we get a complete picture of the patient’s status at that point in time and have a vibrant discussion about treatment options. Depending upon the diagnosis and what radiologists and pathologists see at that point in time and in the patient’s care, it’s [providing] ongoing medical education for everyone while at the same time being practical in care of the patient.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content